SB 205952, a novel semisynthetic monic acid analog with at least two modes of action.

Antimicrobial Agents and Chemotherapy
J M WilsonI Chopra

Abstract

The biological properties of SB 205952, a nitrofuryl oxazole derivative of monic acid, differ from those of the closely related antibacterial agent mupirocin. Compared with mupirocin, SB 205952 has increased antimicrobial potency, an extended spectrum including mupirocin-resistant staphylococci, and rapid bactericidal activity. SB 205952, like mupirocin, is a potent inhibitor of bacterial isoleucyl-tRNA synthetase (IRS) in mupirocin-susceptible organisms but does not inhibit IRS from mupirocin-resistant staphylococci, indicating that SB 205952 has more than one mechanism of action. SB 205952 rapidly inhibits protein, RNA, and DNA syntheses in mupirocin-susceptible and mupirocin-resistant staphylococci. In each case, the effect on RNA synthesis is relaxed by treatment with chloramphenicol, indicating that inhibition of RNA synthesis is probably a secondary consequence of stringent control. It is proposed that SB 205952 possesses one or more mechanisms of action in addition to IRS inhibition, probably mediated by its nitrofuryl component.

References

Nov 1, 1992·The Journal of Antimicrobial Chemotherapy·T H FarmerS W Elson
Sep 1, 1991·The Journal of Hospital Infection·M W Casewell, R L Hill
Jan 1, 1990·The Journal of Applied Bacteriology·C A CherringtonI Chopra
Nov 1, 1987·The Journal of Antimicrobial Chemotherapy·I PhillipsF Baquero
Apr 1, 1985·Antimicrobial Agents and Chemotherapy·R SutherlandA R White
Jul 16, 1973·European Journal of Biochemistry·A DurekovićM R Kula
Oct 1, 1981·Journal of General Microbiology·J M Lopez, P Fortnagel
Jan 1, 1984·Journal of Toxicology and Environmental Health·R L Seither, O R Brown
Sep 1, 1993·Antimicrobial Agents and Chemotherapy·D A JanssenC A Kauffman
May 1, 1946·Proceedings of the National Academy of Sciences of the United States of America·E H Anderson
Jan 1, 1944·The Biochemical Journal·N G Heatley

Citations

Feb 13, 2001·Antimicrobial Agents and Chemotherapy·B OlivaI Chopra
Mar 16, 2002·Journal of Clinical Pathology·R L R Hill
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Dieter BeyerHeike Brötz-Oesterhelt
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Julian G HurdleI Chopra
Jan 12, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N K DuttaJ H Park
Aug 2, 2008·The Journal of Antimicrobial Chemotherapy·Joanne Karen HobbsI Chopra
Sep 18, 2013·Antimicrobial Agents and Chemotherapy·Michael P DraperStuart B Levy
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·B OlivaI Chopra

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.